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Currently the only accepted method (gold standard) for the diagnosis of the fibrotic stages of chronic 
liver disease (CLD) is liver biopsy, to allow histological assessment. Liver biopsy is an invasive 
investigation associated with a range adverse events (e.g. pain, haemorrhage)(1,2) limiting its serial 
usage in clinical practice. Additionally, its use is further reduced by sampling error(3) and because 
histology is in effect a surrogate for clinical outcomes.    
Over recent years, alternative non-invasive biomarkers for the diagnosis of liver fibrosis have been 
developed. Initially developed in chronic viral hepatitis these have since seen their use expanded to 
include all aetiologies of CLD. Such markers can be divided into indirect ‘simple’ markers (e.g. 
transaminases, gamma-glutamyl transferase, platelet count), direct ‘complex’ markers (e.g. 
procollagen peptides I/III, Type IV collagen), cytokines (e.g. interleukin-10, transforming growth 
factor alpha) and imaging. Here, we discuss the clinical utility, limitations and development of non-
invasive biomarkers in their use as diagnostic and prognostic tests.  
Clinical utility of current biomarkers in assessing liver fibrosis   
Indirect ‘simple’ markers 
Indirect markers measure components not directly involved in the fibrosis process. Whilst having the 
advantage of being relatively cheap and easy to perform, they lack diagnostic accuracy for the 
detection of hepatic fibrosis. For example, Kayadibi et al(4) found for the diagnosis of any fibrosis, 
the sensitivity and specificity of alanine aminotransferase to be 68% and for aspartate 
aminotransferase to be 81% and 48% and 83%, respectively,. These correspond to a positive 
predictive value in a low prevalence population (5%) of only 10% and 9%. 
Direct ‘complex’ markers and cytokines 
Direct ‘complex’ markers measure components of the fibrosis pathway and are frequently combined 
as panel markers with perceived improved diagnostic accuracy of individual markers. Currently, 
cross-sectional data suggest that such biomarkers could be used as an alternative to liver biopsy in 
some patients. For example, Guha et al present a clinical utility model showing that the Enhanced 
Liver Fibrosis panel can used to avoid liver biopsy in the diagnosis of advanced liver fibrosis in 88% of 
cases with only 14% of these incorrectly avoiding biopsy. However, these figures drop to 48% and 
21% respectively for the diagnosis of any fibrosis(5). Comparable accuracy  is seen when complex 
markers are tested  are tested in  viral hepataitis(6)  A second use of cross-sectional data is for the 
prediction of liver disease development and prognosis. Kim et al found patients with non-alcoholic 
fatty liver disease (NAFLD) fibrosis (determined by the NAFLD fibrosis score, NFS) had a higher 
probability of all-cause and cardiovascular death (adjusted hazard ratio (aHR) 1.69 and aHR 3.46 
respectively) compared to those with a low NFS(7). These results were partially replicated for the 
simpler biomarkers, aspartate to platelet ratio index (APRI) and the Fibrosis-4 index (FIB4), with both 
associated with increased cardiovascular death and APRI additionally associated with all-cause and 
diabetes related death. Angulo et al had similar findings with NFS, APRI and FIB4 (but not BARD) 
associated with all-cause death and all four markers associated with future clinical liver events(8).    
Similarly to direct markers cytokines have been identified as potential markers of fibrosis as they are 
involved in the regulation of the inflammatory response to liver cell injury and fibrogenesis . A 
number of studies have noted raised levels of cytokines in patients with hepatic fibrosis but few 
have evaluated their diagnostic accuracy.  
Imaging 
The future of non-invasive biomarkers is likely to lie in imaging, allowing the assessment of the 
whole liver, avoiding sampling error and the need for surrogate markers. Whilst transient ultrasound 
elastography (TE) is an easily accessible technology it is subject to operator(9) and subject 
limitations(10). For example, in NAFLD, accuracy in high prevalence (30%) populations is good (PPV 
67%, NPV 93%), but again there is a notable fall in PPV in low prevalence (5%) populations (PPV 18%, 
NPV 99%)(11). It has also been noted that whilst accuracy is maintained the optimal cut-off values of 
TE vary by underlying aetiology(12). However  Magnetic resonance (MR) elastography has excellent 
accuracy for advanced liver fibrosis(13,14) with the main limitation of requiring additional hardware. 
Furthermore, novel MR imaging protocols not requiring contrast or additional hardware are now 
beginning  to emerge (15,16). 
Diagnostic limitations of current biomarkers of fibrosis    
As noted above, large numbers of cross-studies have been undertaken attempting to validate the 
use of non-invasive biomarkers in the diagnosis of liver fibrosis resulting in acceptable diagnostic 
accuracy for advanced fibrosis and cirrhosis (Metavir F3/4). However, their findings have found very 
limited use in early and intermediate CLD.  
Further methodological concerns with these studies exist; few used a development and a validation 
cohort with the majority not replicated, they were often small (n<100) and spectrum bias limits 
applicability with the choice of study population typically tertiary care focused. A heavy reliance on 
area under the receiver operating curves (AUROC) misses the clinical context – with the definition of 
a good AUROC being relative and not absolute. The optimal diagnostic test accuracy metric is are 
determined by the clinical question.   
There have been few longitudinal investigations of serial markers and studies focussed on clinical 
outcomes (as opposed to histology) are challenging but are now starting to emerge. 
Development of biomarkers of NAFLD fibrosis 
Of significant interest now is the ability to detect CLD in a practical manner in the community. For 
this reason we need to be clear on the question we want to answer, for example, do we want to 
detect people with fibrosis or those at risk of fibrosis? Pragmatic population based screening 
strategies need to be employed, focused on risk factors rather than liver enzymes(17), and using 
methods that are easily administered in community settings such as transient elastography(18).  
In the future, researchers need to consider how changes in biomarkers over time are related to CLD 
and clinical outcomes. These have the potential to be powerful tools, transferable to many different 
populations. To date, there are no NAFLD studies considering delta change, however techniques are 
being investigated in hepatitis C virus using both serial serum markers(6) and serial transient 
elastography(19).  
Summary 
The optimal use of non-invasive fibrosis biomarkers in NAFLD depends on the setting and question 
under consideration (Table 1). At present, in secondary care settings there is evidence that some 
non-invasive biomarkers can be used in the diagnosis of advanced liver fibrosis, avoiding the need 
for invasive liver biopsy. However, these same markers and cut-offs may not be similarly suited to 
the identification of CLD and prediction of clinical outcomes in community populations. Furthermore 
further study of imaging techniques and serial measures is needed to fully understand the 
relationship between non-invasive biomarkers and the progression/regression of liver fibrosis in the 
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Utility in defining stage 
of fibrosis 
Useful for full spectrum Most useful for 
advanced fibrosis 
Most useful for 
advanced fibrosis 
Most useful for 
advanced fibrosis 
Most useful for 
advanced fibrosis 










No data presently  
Access to and utility of 
serial assessment 
Not practical due to 
invasive nature 
Easily accessible 
Emerging data for 
utility 
Easily accessible 
Emerging data for 
utility 




Emerging data for utility 
Limited access. 
No data presently for 
utility 
Financial costs* $1,500 per procedure Various, $1-$10 per 
measure 
Various, $70-$200 per 
measure/panel 
Capital costs for 
machine $60,000 




Operational cost $300 
per procedure 
Reliability Sampling error 
(1/50,000th of liver 
sampled) 
Laboratory variability Typically measured at a 
central laboratory 
Operator variability 
Reliability reduced in 
obesity, ascites, liver 
masses, cholestasis 
Limited data available  
Performance location Hospital Community or hospital Community or hospital Community or hospital Hospital 
*costs obtained from Appendix 9 in Crossan C, Tsochatzis EA, Longworth L, Gurusamy K, Davidson B, Rodríguez-Perálvarez M, et al. Cost-effectiveness of 
non-invasive methods for assessment and monitoring of liver fibrosis and cirrhosis in patients with chronic liver disease: systematic review and economic 
evaluation. Health Technol Assess 2015;19(9). 
 
 
